Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327
·
clinicaltrials.gov ↗
RECRUITING
Status
1000
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG:
Chimeric Antigen Receptor
Sponsor
Ruijin Hospital